KRAS and colorectal neoplasm: First, the response to treatments with KRAS G12C inhibitor drugs was less promising in patients with colorectal cancer than in patients with metastatic lung cancer, likely due to the different biology of colorectal tumors, in which there are often multiple mutations and many signaling pathways involved.